Jupiter Neurosciences(JUNS.US)

Last Updated 19:00:00 ET
longbridge loading

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga_article·
US
SDEV
-1.94%
US
GELS
+16.66%
US
PHGE
+59.60%
benzinga_article·
US
SDEV
-1.94%
US
GELS
+16.66%
US
PHGE
+59.60%

Jupiter Neurosciences prices registered direct offering at USD 2 million

PUBT·
US
JUNS
-35.94%
PUBT·
US
JUNS
-35.94%

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | JUNS Stock News

StockTitan·
US
JUNS
-35.94%
US
VHT
+0.27%
US
PBE
+1.60%
StockTitan·
US
JUNS
-35.94%
US
VHT
+0.27%
US
PBE
+1.60%

JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1

MSN·
US
JUNS
-35.94%
US
BBH
+0.96%
US
ARKG
+5.05%
MSN·
US
JUNS
-35.94%
US
BBH
+0.96%
US
ARKG
+5.05%

Jupiter Neurosciences shares are trading higher after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.

benzinga_article·
US
JUNS
-35.94%
US
IBB
+2.27%
US
BIB
+4.98%
benzinga_article·
US
JUNS
-35.94%
US
IBB
+2.27%
US
BIB
+4.98%

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | JUNS Stock News

StockTitan·
US
JUNS
-35.94%
US
VHT
+0.27%
US
FBT
+2.14%
StockTitan·
US
JUNS
-35.94%
US
VHT
+0.27%
US
FBT
+2.14%
© 2026 Longbridge｜Disclaimer